Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD

DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and data will be presented during Dexcom symposia and presentations at the 17th International Conference on Advanced Technologies and Treatments for Diabetes, held March 6-9, in Florence.

“As the pioneer in biosensing, since last year’s ATTD, Dexcom has moved at an extraordinary pace. We launched G7 in 16 additional countries, released Dexcom ONE+ and are today announcing the phased launch of ‘Direct-to-watch’, that’s two best-in-class products and a feature designed to empower even more people living with diabetes. Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.

Driving access to best-in-class CGM technology

Dexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023. The company’s latest sensor, Dexcom ONE+, which was built based on user and HCP feedback and is designed to be easy to use for anyone living with diabetes, has also launched in eight markets within one month of first becoming available.

Delivering exceptional end-user experiences with direct connectivity to Apple Watch

Showing a commitment to not only expanding access to life-changing CGM but also to improving the experience for those already using Dexcom CGM, Dexcom announced that ‘direct to Apple Watch’ functionality for Apple Watch will have a phased launch available to all G7 iOS users everywhere by the end of the second quarter of this year. The announcement means that Dexcom G7 will soon be the only CGM system that can connect directly to Apple Watch without always needing to carry an iPhone.^† People choosing Dexcom G7 to help manage their diabetes will have access to ‘direct to Apple Watch’ as soon as it launches in their country.